Chiome Bioscience Inc.

4583

JP3205350006

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 02:30:00 2026-03-12 EDT			5-day change	1st Jan Change
111.00 ^JPY	-1.77%		+1.83%	+3.74%

02-10	Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-14	Chiome Bioscience Inc. announced that it has received ¥214.971 million in funding from Next Growth Co., Ltd.	CI

Chiome Bioscience Starts Phase I Trial of ADCT-701 in Neuroendocrine Tumors

Published on 07/29/2024 at 11:03 pm EDT - Modified on 07/29/2024 at 11:04 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Chiome Bioscience Inc.

02-10	Chiome Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-14	Chiome Bioscience Inc. announced that it has received ¥214.971 million in funding from Next Growth Co., Ltd.	CI
11-27	Chiome Bioscience Inc. announced that it expects to receive ¥214.971 million in funding from Next Growth Co., Ltd.	CI
11-11	Chiome Bioscience Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-06	Alfresa Holdings Corporation Kidswell Bio Corporation. Chiome Bioscience Inc. and Mycenax Biotech Inc Announces Agreement in Principle to Establish Joint Venture for the Manufacturing of Drug Substance and Formulations of Biosimilars	CI
25-02-27	Chiome Bioscience Inc. Announces Collaborative Exploratory Research Agreement with OmniAb, Inc	CI
25-02-13	Japan Stocks Rise as Wholesale Inflation Fuels Rate Hike Bets	MT
25-02-12	Chiome Bioscience, Ceinge Biotecnologie Report Cancer Immunotherapy Findings in Cell Death Discovery	MT
25-01-21	Chiome Bioscience Publishes Phase I Study Results for CBA-1205	MT
24-12-19	Chiome Bioscience Inc. Announces Publication on CBA-1205 Non-Clinical Data	CI
24-12-18	Chiome Bioscience Extends Master Services Agreement with Chugai Pharmaceutical	MT
24-12-18	Chiome Bioscience Inc. and Chugai Pharmaceutical Co., Ltd. Agree with Extension of the Master Services Agreement	CI
24-11-20	Chiome Bioscience Licenses Anti-CX3CR1 Antibody to Asahi Kasei Pharma	MT
24-11-20	Chiome Announces Exclusive Licensing Agreement for Anti-CX3CR1 Antibody	CI
24-07-29	Chiome Bioscience Starts Phase I Trial of ADCT-701 in Neuroendocrine Tumors	MT

Chiome Bioscience Inc. is a company mainly engaged in the research and development of antibody drugs, and the provision of development support services. The Company operates in two business segments. The Drug Discovery segment is engaged in the research and development of specific antibodies based on new antigens and mechanisms and licensing to pharmaceutical companies. The Drug Discovery Support segment is engaged in development of lead antibodies for therapeutic drugs in collaborating with pharmaceutical companies in Japan and overseas.

Employees

Sector

Biotechnology & Medical Research

More about the company